Publications by authors named "A L Nordstroem"
Article Synopsis
- PTSD affects over 13 million people in the U.S. and has limited treatment options, leading to a study of balovaptan, a vasopressin 1a receptor antagonist, to evaluate its effectiveness.
- In a Phase 2 trial, 57 adults were screened, and 29 were randomly assigned to either balovaptan or a placebo, with no significant differences in PTSD symptom severity observed after 12 weeks.
- Both treatment groups tolerated the medication well, but adverse events were reported more frequently in the balovaptan group than in the placebo group.
Background: Huntington's disease (HD) is a rare, neurodegenerative disease and its complex motor, cognitive and psychiatric symptoms exert a lifelong clinical burden on both patients and their families.
Objective: To describe the clinical burden and natural history of HD.
Methods: This longitudinal cohort study used data from the linked Swedish national registries to describe the occurrence of comorbidities (acute and chronic), symptomatic treatments and mortality in an incident cohort of individuals who either received the first diagnosis of HD above (adult onset HD; AoHD) or below (juvenile-onset HD; JoHD) 20 years of age, compared with a matched cohort without HD from the general population.
Background: Generic health-related quality of life (HRQoL) scales are increasingly being used to assess the effects of new treatments in schizophrenia. The objective of this study is to better understand the usefulness of generic and condition specific HRQoL scales in schizophrenia by analyzing their correlates.
Methods: Data formed part of the Pattern study, an international observational study among 1379 outpatients with schizophrenia.
Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study.
Psychiatry Res
June 2019
Treatment-Resistant Schizophrenia (TRS) and Non-Treatment-Resistant Schizophrenia (NTRS) may represent different subtypes of schizophrenia. However, few studies have investigated their PANSS symptom dimensions by Exploratory (EFA) or Confirmatory (CFA). Data from the present study are derived from 1429 patients of the Pattern study.
View Article and Find Full Text PDFHealth-related quality of life (HRQoL) in patients with schizophrenia is related to the severity of psychiatric symptoms. The objective of this study is to analyze whether the symptoms that influence HRQoL are similar in women and men. Data were part of the Pattern study, an international observational investigation which collected data from 1379 outpatients with schizophrenia.
View Article and Find Full Text PDF